Relugolix in combination with estradiol/norethindrone acetate for moderate to severe symtpoms of uterine fibroids
Relugolix is a small molecule that binds to the gonadotropin-releasing hormone receptor in the pituitary gland, decreasing the release of hormones which control oestrogen and progesterone production by the ovaries. Results from clinical trials demonstrated that relugolix in combination with estradiol and norethisterone acetate reduced menstrual bleeding in women with uterine fibroids. Relugolix is administered orally, and if licensed would offer an additional treatment option for women moderate to severe symptoms associated with uterine fibroids.
Leuprorelin acetate for the preservation of ovarian function in premenopausal women with neoplastic disease undergoing chemotherapy
Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) analogue that may preserve ovarian function by preventing early stage development of ovarian follicles from maturation. This may decrease the number of follicles that are vulnerable to chemotherapy. The protective effects of GnRH analogues have also been associated with a decrease in utero-ovarian blood flow which leads to decreased exposure of the ovaries to the chemotherapeutic agents. If licensed, leuprorelin acetate, given by injection, may offer a simpler, less invasive and less expensive alternative when compared to current strategies for preserving ovarian function in women undergoing chemotherapy.
Sonata™ System for the removal of uterine fibroids
The Sonata™ System (previously VizAblate®), developed by Gynesonics, is an incisionless, transcervical system that combines ultrasound image guidance with radiofrequency (RF) ablation. The system is designed to treat symptomatic uterine fibroids in a hospital outpatient setting, depending on anaesthetic requirements.
SoftVue™ system for diagnostic breast imaging
The SoftVue™ system developed by Delphinus Medical Technologies is a non-ionising, non-compressing, and non-invasive whole breast imaging device. Its intended use is for the examination of breasts for the presence of suspicious masses. It is not intended for use as a replacement of screening mammography.
Lyrette™ for stress urinary incontinence
Lyrette™, formerly known as Renessa, is a transurethral device developed by Verathon Medical Ltd to deliver non-ablative radiofrequency energy to women with stress urinary incontinence (SUI) caused by hypermobility. It is intended to provide a treatment option for SUI before invasive surgery.
PartoSure™ Time to Delivery test in suspected premature labour
PartoSure™ Time to Delivery (TTD) test is a novel, rapid point-of-care test, developed by AmniSure International (a QIAGEN company). The test is designed to help predict the time to delivery when pregnant women report signs and symptoms suggestive of labour between 20 and 37 weeks of gestation with clinically intact amniotic membranes.
IUB™ SCu300A intrauterine device for contraception
The IUB™ SCu300A is an intrauterine device (IUD) intended for women who need long-acting reversible contraception. It is in development by Ocon Medical Ltd. The device is made from memory metal, also called shape memory alloy, and copper. It is designed to work in a similar way to other IUDs by stopping the sperm and …
Ospemifene for vulvo-vaginal atrophy in postmenopausal women
Ospemifene is intended to be used as first or second line therapy for the treatment of vulvo-vaginal atrophy (VVA) in post-menopausal women. If licensed, it may provide an alternative treatment option for this patient group. Ospemifene is an orally active, selective oestrogen receptor modulator (SERM) with agonistic effects on vaginal epithelium in post-menopausal women. It …